Glucagon-like peptide-1 (GLP-1), an incretin hormone renowned for its role in post-meal blood sugar regulation and glucose-dependent insulin secretion, has gained attention as a novel treatment for diabetes through GLP-1 receptor agonists (GLP-1-RA). Despite their efficacy, concerns have been raised regarding the potential associations between GLP-1-RA and certain malignancies, including medullary thyroid cancer. However, evidence of its association with prostate cancer (PCa) remains inconclusive. This review delves into the intricate relationship between GLP-1-RA and PCa, exploring the mechanisms through which GLP-1-Rs may impact PCa cells. We discuss the potential pathways involving cAMP, ERK, AMPK, mTOR, and P27. Furthermore, we underscore the imperative for additional research to elucidate the impact of GLP-1-RA treatment on PCa progression, patient outcomes, and potential interactions with existing therapies. Translational studies and clinical trials are crucial for a comprehensive understanding of the role of GLP-1-RA in PCa management.
胰高血糖素样肽-1（GLP-1）作为一种肠促胰岛素激素，以其在餐后血糖调节和葡萄糖依赖性胰岛素分泌中的作用而闻名，通过GLP-1受体激动剂（GLP-1-RA）已成为糖尿病治疗的新兴方向。尽管其疗效显著，但GLP-1-RA与某些恶性肿瘤（包括甲状腺髓样癌）的潜在关联已引发关注。然而，其与前列腺癌（PCa）之间的关联证据仍不明确。本综述深入探讨了GLP-1-RA与PCa之间复杂的关系，探究了GLP-1受体可能影响PCa细胞的机制。我们讨论了涉及cAMP、ERK、AMPK、mTOR和P27的潜在通路。此外，我们强调亟需进一步研究以阐明GLP-1-RA治疗对PCa进展、患者预后以及与现有疗法潜在相互作用的影响。转化研究和临床试验对于全面理解GLP-1-RA在PCa治疗中的作用至关重要。
肿瘤(癌症)患者之家